艾迪药业2025年净利预亏1600万元至2400万元

Core Viewpoint - Eddie Pharmaceutical (688488) forecasts a net profit loss of approximately 16 million to 24 million yuan for the year 2025, with a year-on-year decrease in loss margin of about 88.67% to 83% [1] Financial Performance - The primary reason for the change in net profit is attributed to an increase in revenue from innovative anti-HIV drugs and the operational data from the merger with Nanda Pharmaceutical, leading to a gross profit increase of approximately 267 million yuan compared to the previous year [1] - Sales expenses for the reporting period increased by approximately 92 million yuan compared to the previous year due to intensified promotion of new drugs and the operational data from the merger with Nanda Pharmaceutical [1]